Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (101) clinical trials

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...


Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Treatment of the metastatic renal cell carcinoma (mRCC) has experienced fundamental changes within a very short period of time. In the past few years, introduction of various new substances for the treatment of mRCC has therefore resulted in new scientific research questions. Temsirolimus and sunitinib are current standard therapies in ...

Phase N/A

Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematologic Disease

PRIMARY OBJECTIVES: I. To determine the one year survival of patients undergoing umbilical cord blood transplantation (UCBT) after a myeloablative preparative regimen consisting of cyclophosphamide (CY), fludarabine phosphate (fludarabine [FLU]), and fractionated total body irradiation (TBI). SECONDARY OBJECTIVES: I. Incidence of transplant-related mortality (TRM) at 6 months. II. Chimerism at ...


A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)

This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 INCB050465 treatment regimens in subjects with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.


Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single-agent rituximab ...


Double Cord Versus Haploidentical (BMT CTN 1101)

Reduced intensity conditioning (RIC) blood or marrow transplantation (BMT) has allowed older and less clinically fit patients to receive potentially curative treatment with allogeneic HCT for high risk or advanced hematological malignancies. Patients lacking an HLA-matched sibling may receive a graft from a suitably HLA-matched unrelated donor. However, up to ...


A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Mantle Cell Lymphoma (MCL) and Healthy Volunteers

Chronic lymphocytic leukemia (CLL) and its lymphoma variant, small lymphocytic lymphoma (SLL) were for decades considered diseases caused by the progressive accumulation of abnormal lymphocytes. The prevailing view being that CLL and SLL disease processes were driven by an underlying defect in apoptosis. While resistance to apoptosis appears to be ...

Phase N/A

Rituximab Bendamustine Hydrochloride and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES Primary To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS) compared to RB alone in patients 60 years of age with previously untreated mantle cell lymphoma. To determine whether the addition of lenalidomide to a consolidation regimen of ...


A clinical trial seeking patients for a research study for the treatment of Recurrent Mycosis Fungoides/Sezary Syndrome, ESSENTIAL THROMBOCYTHEMIA, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Lymphoblastic Lymphoma, Refractory Cytopenia With Multilineage Dysplasia, anaplastic large cell lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Anemia with Excess of Blasts, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Waldenstrom's Macroglobulinemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Childhood Myelodysplastic Syndromes, Recurrent Childhood Acute Myeloid Leukemia, chronic phase chronic myelogenous leukemia, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Relapsing Chronic Myelogenous Leukemia, Chronic myelomonocytic leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, de Novo Myelodysplastic Syndromes, Childhood Chronic Myelogenous Leukemia, Myelosclerosis with myeloid metaplasia, Testicular Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Intraocular Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Secondary Acute Myeloid Leukemia, Hepatosplenic T-cell Lymphoma, Polycythemia Vera, Blast Crisis, T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Angioimmunoblastic Lymphadenopathy, Refractory Hairy Cell Leukemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Multiple Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Noncutaneous Extranodal Lymphoma, Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Adult Acute Myeloid Leukemia With Del(5q), Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Post-transplant Lymphoproliferative Disorder, Small Intestine Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent/Refractory Childhood Hodgkin Lymphoma, Childhood Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Nodal Marginal Zone B-cell Lymphoma, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0

This study will determine whether peripheral blood flow cytometry can reduce or replace invasive bone marrow examinations in patients with slow growing lymphomas. Patients with certain types of slow growing (indolent) lymphomas, including the most common sub-type, follicular lymphoma, require a bone marrow examination for staging of their lymphoma. This ...

Phase N/A